ERJ Open Research最新文献

{"title":"Cystic fibrosis transmembrane conductance regulator therapy with elexacaftor/tezacaftor/ivacaftor reduces detection of hallmark cystic fibrosis pathogens in Europe: progress made but no time to slow down.","authors":"Katharina Schütz, Sophia T Pallenberg, Ilona Rosenboom, Anna-Maria Dittrich","doi":"10.1183/23120541.00211-2025","DOIUrl":"10.1183/23120541.00211-2025","url":null,"abstract":"<p><p><b>ETI reduces pathogen detection rates in respiratory samples, yet a significant proportion of pwCF continue to harbour hallmark pathogens putting them at risk of more rapid decline in lung function</b> https://bit.ly/3DAcKKH.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Locus of control and breathlessness: a cross-sectional analysis of 28 730 people.","authors":"Max Olsson, Jacob Sandberg, Slavica Kochovska, Anders Blomberg, Mats Börjesson, Gunnar Engström, Andrei Malinovschi, Magnus Sköld, Per Wollmer, Kjell Torén, Carl Johan Östgren, David C Currow, Magnus Ekström","doi":"10.1183/23120541.00908-2024","DOIUrl":"10.1183/23120541.00908-2024","url":null,"abstract":"<p><strong>Background: </strong>Long-term pathological breathlessness is a life-limiting symptom that risks taking control of the individual's life. We aimed to evaluate how locus of control (LOC), an individual's perceived control of present and past life events, relates to breathlessness in a middle-aged general population.</p><p><strong>Methods: </strong>A population-based, cross-sectional analysis of people aged 50-64 years was conducted in the Swedish CArdioPulmonary bioImage Study (SCAPIS). Breathlessness was measured using the modified Medical Research Council (mMRC) breathlessness scale. LOC was assessed using five-point scales related to work, life events, perceived future, treated by other people, past changes and life improvements. The LOC factors were dichotomised as having an external or internal LOC. Logistic regression was used to examine the association between external LOC and presence of moderate/severe breathlessness (mMRC ≥2). Associations between external LOC and higher breathlessness severity score (mMRC 0-4) were analysed using ordinal regression. The models were adjusted for age, sex, education level, pack-years of smoking, body mass index, lung function, depression and cardiorespiratory diseases.</p><p><strong>Results: </strong>Of 28 730 participants (52% women), 4% experienced breathlessness. Breathlessness was related to external LOC in relation to life events (odds ratio (OR) 1.47, 95% confidence interval (CI) 1.26-1.71), future (OR 1.89, 95% CI 1.53-2.34), treated unfairly (OR 1.73, 95% CI 1.42-2.09), past changes (OR 1.50, 95% CI 1.30-1.74) and life improvements (OR 2.91, 95% CI 2.35-3.59). External LOC was associated with increased breathlessness severity.</p><p><strong>Conclusion: </strong>External LOC is associated with experiencing worse breathlessness, and the identified LOC factors can be considered in future intervention studies aiming to reduce the suffering from breathlessness.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Respiratory infections after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry.","authors":"Mordechai Pollak, Simone Gambazza, Annalisa Orenti, Virginia De Rose, Dario Prais, Eitan Kerem, Meir Mei Zahav","doi":"10.1183/23120541.01248-2024","DOIUrl":"10.1183/23120541.01248-2024","url":null,"abstract":"<p><strong>Background: </strong>Elexacaftor/tezacaftor/ivacaftor (ETI) has improved outcomes for people with cystic fibrosis (pwCF). This study evaluated changes in airway microbiological infection status after initiating ETI.</p><p><strong>Methods: </strong>Using the European Cystic Fibrosis Society registry, pwCF who started ETI between 2019 and 2021 were identified. The changes in microbiological status from 1 year before to 1 year after ETI initiation, were compared with the changes seen from 3 to 1 years before starting ETI. Mixed-effect regression models were used to analyse changes. Data from 2 years after initiation were examined for those starting ETI in 2019-2020.</p><p><strong>Results: </strong>Included were 15 739 pwCF from 30 countries. In the year before ETI, 38.4% were positive for <i>Pseudomonas aeruginosa</i> (PsA) and 36.4% for methicillin-sensitive <i>Staphylococcus aureus</i> (MSSA). After ETI, 38.7% of PsA-positive and 47.2% of MSSA-positive patients transitioned to negative status, compared with 14.8% and 29.1%, respectively, in the previous years. The adjusted difference in transitioning to negative was 14.6% (PsA) and 17.1% (MSSA), both p<0.001. Similar improvements were seen for <i>Burkholderia cepacia</i> complex and <i>Stenotrophomonas maltophilia</i>. For those starting ETI in 2019-2020, PsA positivity remained low over 2 years, decreasing from 46.8% pre-ETI to 30.4% and 27.7% at 1 and 2 years after ETI treatment.</p><p><strong>Conclusion: </strong>One year after starting ETI, many pwCF who were initially positive for various CF-related pathogens, shifted to a negative status, a change less common before ETI. These findings suggest that ETI reduces airway infections, with benefits extending into the second year of treatment, although some pwCF continue to carry these pathogens despite treatment.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral airway function and disease burden in COPD.","authors":"Martin Färdig, Karin Lingman, Karin Lisspers, Björn Ställberg, Christer Janson, Marieann Högman, Andrei Malinovschi","doi":"10.1183/23120541.01078-2024","DOIUrl":"10.1183/23120541.01078-2024","url":null,"abstract":"<p><strong>Background: </strong>While oscillometry appears advantageous over spirometry in detecting peripheral airway dysfunction, a feature of COPD, further research on its role in disease monitoring is needed. The objectives of the present study were to analyse the associations between oscillometry by impulse oscillometry (IOS) and forced oscillation technique (FOT) and airway obstruction, health status, dyspnoea and future exacerbations in COPD.</p><p><strong>Methods: </strong>Oscillometry and disease burden were assessed in 150 adults with COPD within the Tools Identifying Exacerbations study. At 5 Hz, abnormal resistance (<i>R</i> _rs5) and reactance (<i>X</i> _rs5) were defined as <i>z</i>-scores >1.645 and <-1.645 sd, respectively, whereas a mean difference in reactance between inspiration and expiration >2.80 cmH₂O·L^-1·s^-1 represented abnormal Δ<i>X</i> _rs5. Forced expiratory volume in 1 s (FEV₁), COPD Assessment Test (CAT) and modified Medical Research Council (mMRC) scores were obtained. Medical records were reviewed for future exacerbations (≥1) between baseline and 1 and 3 years, respectively.</p><p><strong>Results: </strong>Abnormal oscillometry correlated with disease burden, with the highest risk observed for severe airway obstruction (FEV₁ <50% pred): odds ratios with 95% confidence intervals ranging from 4.80 (1.93-12.0) to 18.0 (7.13-45.3) for <i>R</i> _rs5, <i>X</i> _rs5 and Δ<i>X</i> _rs5, followed by moderate to severe dyspnoea (mMRC ≥2) for Δ<i>X</i> _rs5, COPD health status (CAT ≥10) for <i>R</i> _rs5 and Δ<i>X</i> _rs5 and future exacerbations (1 and 3 years) for <i>R</i> _rs5 and <i>X</i> _rs5, respectively, with odds ratios (95% CI) ranging from 2.77 (1.27-6.05) to 3.98 (1.38-11.5).</p><p><strong>Conclusions: </strong>Abnormal oscillometry may be relevant in the evaluation of COPD patients, including the prediction of future exacerbation risk.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare variants in <i>STAB2</i> in patients with chronic thromboembolic pulmonary hypertension.","authors":"Mark W Dodson, Kristina Allen-Brady, Jeffrey Stevens, Meghan M Cirulis, Mona Alotaibi, Timothy M Fernandes, Nick H Kim, Kim M Kerr, Demosthenes G Papamatheakis, David S Poch, Julianna Desmarais, D Hunter Best, Nathan D Hatton, John J Ryan, C Gregory Elliott, Lisa A Cannon-Albright","doi":"10.1183/23120541.01322-2024","DOIUrl":"10.1183/23120541.01322-2024","url":null,"abstract":"<p><strong>Background: </strong>The pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) is poorly understood. Studies of the genetic risk factors for CTEPH are likely to improve our understanding of CTEPH pathogenesis and may lead to novel treatment and prevention strategies. Genetic analysis focused on shared gene variants in high-risk disease pedigrees can aid in the identification of rare variants with a strong effect on disease risk.</p><p><strong>Methods: </strong>We identified 13 CTEPH high-risk pedigrees and performed whole-exome sequencing in 22 CTEPH cases from these pedigrees, focusing on rare and deleterious variants that were shared between related CTEPH cases. We validated CTEPH candidate gene variants in two independent CTEPH cohorts, one from Utah (n=78) and one from the University of California San Diego (n=238), and compared them to controls from the UK Biobank.</p><p><strong>Results: </strong>A rare and predicted deleterious missense variant in <i>STAB2</i> was identified in two related CTEPH cases. Qualifying <i>STAB2</i> variant alleles were observed more frequently in both CTEPH cohorts (pooled allele frequency 4.6%) than in subjects from the UK Biobank with a history of pulmonary embolism (PE) (allele frequency 2.2%, p=0.0002) or without a history of PE (allele frequency 1.9%, p<0.0001). CTEPH subjects with qualifying <i>STAB2</i> variants had elevated levels of plasma von Willebrand Factor (vWF) and factor VIII, consistent with the known role of <i>STAB2</i> as a genetic regulator of circulating vWF levels.</p><p><strong>Conclusions: </strong>Rare variants in <i>STAB2</i> are identified in a CTEPH high-risk pedigree and are over-represented in nonrelated CTEPH cases compared to controls with PE. These data suggest that <i>STAB2</i> is a CTEPH risk gene.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The genetics of chronic thromboembolic pulmonary hypertension: no longer a stab in the dark.","authors":"David Montani, Mark Toshner","doi":"10.1183/23120541.00551-2025","DOIUrl":"10.1183/23120541.00551-2025","url":null,"abstract":"<p><p><b>As our understanding of the genetic basis of CTEPH deepens, we are moving closer to predicting which PE survivors are at greatest risk and to intervening before irreversible vascular remodelling occurs</b> https://bit.ly/3RTcE4k.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-molecular-weight hyaluronic acid improves regeneration of cystic fibrosis airway epithelium.","authors":"Damien Adam, Emilie Luczka-Majérus, Julie Cellier, Charline Dos Santos-Dietz, Claire Kileztky, Arnaud Bonnomet, Christophe Ruaux, Edouard Sage, Myriam Polette, Michel Abély, Christelle Coraux","doi":"10.1183/23120541.00799-2024","DOIUrl":"10.1183/23120541.00799-2024","url":null,"abstract":"<p><strong>Background: </strong>Cystic fibrosis is characterised by defective mucociliary clearance, chronic lung infection and exaggerated neutrophilic inflammation. Airway epithelium damage and remodelling affect lung defence functions and are therefore important components of lung pathology progression in cystic fibrosis. Identifying compounds that favour mucociliary clearance by improving airway epithelial structure and regeneration is therefore crucial for patients with cystic fibrosis.</p><p><strong>Materials and methods: </strong>Using air-liquid interface culture of human airway epithelial cells obtained from patients with cystic fibrosis, we examined the influence of low-molecular-weight hyaluronic acid (LMW-HA) (∼40 kDa) on the regeneration and remodelling of cystic fibrosis human airway epithelial cells.</p><p><strong>Results: </strong>Our results show that LMW-HA normalises cystic fibrosis epithelial regeneration, even in an inflamed environment, by preventing remodelling in terms of epithelial height and basal cell hyperplasia, by avoiding inflammation-related goblet cell hyperplasia and by stimulating multiciliated cell differentiation. Because remodelling is mainly due to either intrinsic inflammation of cystic fibrosis human airway epithelial cells or an extrinsic inflammatory environment, we examined the impact of LMW‑HA on epithelial interleukin 8 pro-inflammatory chemokine and found that it exerts an anti-inflammatory effect, evidenced by reduced epithelial interleukin 8 expression and secretion.</p><p><strong>Conclusion: </strong>We report here that LMW-HA prevents cystic fibrosis human airway epithelial cell remodelling and normalises its cell structure, probably through the epithelial cell inflammatory phenotype modulation, and improves multiciliated cell differentiation by a mechanism that is independent of its anti-inflammatory effect. These results demonstrate that LMW-HA should be considered as a therapeutic candidate for the treatment of cystic fibrosis lung disease.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"6 min of walking to capture aerobic capacity.","authors":"Gael Deboeck, Gabriel Dias Rodrigues, Marco Vicenzi","doi":"10.1183/23120541.01354-2024","DOIUrl":"10.1183/23120541.01354-2024","url":null,"abstract":"<p><p><b>6MWD lower than 440 m in PAH patients probaly indicates very limited haemodynamic adpatation to exercise, and is linearly associated with higher <i>V̇</i> _E/<i>V̇</i> _CO₂ , suggesting more altered chemo-, baro- or metabo-reflex sensitivity in those patients</b> https://bit.ly/3QKQ51b.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implications of reference equations for interpretation of spirometry in three African countries: a cross-sectional study.","authors":"Denise Banze, Claire J Calderwood, Celina Nhamuave, Edson T Marambire, Alfred Mfinanga, Leyla Larsson, Akanksha Mimi Malhotra, Lilian T Minja, Olena Ivanova, Lindsay Zurba, Norbert Heinrich, Rashida A Ferrand, Katherine Fielding, Katharina Kranzer, Andrea Rachow, John R Hurst, Celso Khosa","doi":"10.1183/23120541.00932-2024","DOIUrl":"10.1183/23120541.00932-2024","url":null,"abstract":"<p><strong>Background: </strong>The Global Lung Function Initiative (GLI) and American Thoracic Society recently endorsed a race-composite spirometry reference equation (\"GLI Global\"). Africa (outside North Africa) is not represented in the underlying dataset; GLI Global has not been evaluated in the region. We evaluated the fit and diagnostic implications of GLI and African (identified by scoping review) reference equations in three East/Southern African countries.</p><p><strong>Methods: </strong>Among healthy participants from a tuberculosis household contact cohort study in Mozambique, Tanzania and Zimbabwe (age ≥10 years) with post-bronchodilator spirometry we calculated forced expiratory volume in 1 s (FEV₁), forced vital capacity (FVC) and FEV₁/FVC z-scores using different equations, the proportion of people with obstructive airways disease or preserved-ratio-impaired spirometry by different equations. We compared these measures across reference equations.</p><p><strong>Results: </strong>In total, 806 healthy people had good-quality post-bronchodilator spirometry. Across GLI equations, \"African American\" fitted best (mean±sd FEV₁ z-score -0.12±1.20, mean FVC z-score -0.35±1.19). Compared with \"African American\", GLI Global resulted in twice as many people being identified as having preserved-ratio impaired spirometry (22% <i>versus</i> 11%) with a similar proportion having obstruction (4.2% <i>versus</i> 3.8%). Reference equations developed in Africa conferred similar fit compared with the GLI African American equation.</p><p><strong>Conclusions: </strong>Reference equations have clinical and public health implications that demand careful consideration, particularly in resource-constrained environments. Use of GLI Global may result more people being identified as having lung function impairment. Further work that includes clinical outcomes is needed to ensure that GLI Global is globally representative. The key limitation of this work is the potential for people with undiagnosed respiratory disease to have been included in the analysis.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deupirfenidone (LYT-100) in post-acute sequelae of SARS-CoV-2 with respiratory complications.","authors":"Tejaswini Kulkarni, Joel Santiaguel, Raminder Aul, Mark Harnett, Julie Krop, Michael C Chen, Camilla S Graham, Toby M Maher","doi":"10.1183/23120541.01142-2024","DOIUrl":"10.1183/23120541.01142-2024","url":null,"abstract":"<p><strong>Introduction: </strong>The pathophysiology of respiratory complications in post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) is poorly understood, but a high incidence of progressive pulmonary fibrosis was anticipated. Deupirfenidone (LYT-100) is a selectively deuterated form of pirfenidone that retains antifibrotic and anti-inflammatory activity but with improved tolerability. This study evaluated the safety and efficacy of deupirfenidone in PASC patients with respiratory complications.</p><p><strong>Methods: </strong>Global, double-blind, randomised placebo-controlled trial evaluating 750 mg deupirfenidone twice daily <i>versus</i> placebo for 3 months in PASC patients with respiratory complications following hospitalisation for acute COVID-19 infection severe enough to necessitate supplemental oxygen (NCT04652518).</p><p><strong>Results: </strong>185 patients were randomised and treated (95 with deupirfenidone, 90 with placebo), with 177 included in the modified intention-to-treat population. The mean age was 54.5 years, 62.7% were male and 10.7% had prior mechanical ventilation. The 6-min walk distance improved across both arms between baseline and day 91 (deupirfenidone 44.3 m (95% CI 24.8-63.8 m) <i>versus</i> placebo 48.8 m (95% CI 29.2-68.4 m); p=0.70). The most common treatment-emergent adverse events (TEAEs) for deupirfenidone <i>versus</i> placebo were nausea (9.5% <i>versus</i> 1.1%), upper abdominal discomfort (5.3% <i>versus</i> 2.2%) and dyspepsia (6.3% <i>versus</i> 1.1%). TEAEs leading to trial drug discontinuation were 11.6% for deupirfenidone and 4.4% for placebo. The proportion of discontinuations considered at least possibly related to treatment was 8.6% for deupirfenidone and 2.4% for placebo.</p><p><strong>Discussion: </strong>Most patients with PASC and respiratory complications showed significant improvement over 91 days irrespective of treatment assignment. Deupirfenidone was well tolerated, with low rates of TEAEs, which supports further investigation in patients with idiopathic pulmonary fibrosis.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"11 4","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}